Organ Transplantation Market Size was valued at USD 7.3 billion in 2023 and is projected to grow from USD 7.99 Billion in 2024 to USD 15.16 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.33% during the forecast period (2024 - 2032). The main market drivers boosting market expansion are the rising need for cutting-edge tissue transplant goods and organ transplants to cure organ failure.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
An organ or living tissue can be implanted in another body or part of the same body through the medical technique known as transplantation. The global growth in the need for organ transplants may be related to a spike in the number of severe illnesses, which in turn causes an upsurge in organ failures. For instance, diabetes and elevated blood pressure are among the leading causes of failure of the kidneys, in which transplants of kidneys or dialysis are the only options for therapy to keep a patient alive. One of the major reasons driving market expansion is the increased demand for these operations and the introduction of fresh solutions for avoiding the breakdown of these procedures.
Additionally, several government and non-government organizations are assisting in raising awareness of the significance of organ donation. Over the years, the market has seen a lot of strategic alliances. The great need for organ transplantation has resulted from increased organ failure instances. Numerous significant businesses consistently focus on expanding their product portfolios to increase the number of transplantations performed through partnerships. One significant aspect predicted to drive the global transplantation market growth is a significant increase in the number of transplants performed. Chronic illnesses like cancer, renal disease, COPD, and lupus, which are becoming more common, typically cause significant tissue and organ damage. One of the most important growing factors for the world economy is the increase in organ failures.
Numerous reasons, such as blood loss, poisoning, drug addiction, severe trauma, leukemia, sepsis, and other acute diseases, are frequently blamed for organ failure. This has resulted from an enormous worldwide requirement for tissue and organ transplantation—including organs like the kidneys, liver, heart, and lungs. Globally, there is a substantial need for tissue and transplantation of organs, particularly for the kidney, heart, liver, and lungs. In addition, cutting-edge technologies are being used to overcome immunologic obstacles, including decellularization and recellularization, three-dimensional (3D) bioprinting, and interspecies organogenesis. Additionally, most individuals in poor nations are ignorant of the options available for these surgeries, and many ineffective reimbursement practices exist. Organ failure can be brought on by a variety of factors, including poor eating habits, alcohol intake, inactivity, and drug usage.
In November 2023, nine technology start-ups were launched from Sastra University’s business incubators. One of them was a medical transplant box that can be 3D printed and connected to the Internet of Things (IoT). It weighs only five kilograms. This means drugs, blood samples, and other body fluids, including human organs, can be moved using drones, together with critical care supplies. Others were natural supplements for cows that increased milk yields, hazardous operation robots, and an automatic irrigation system called an e-toggle that is controlled remotely by farmers. These products were commissioned by Nidhi Bansal, who is Scientist G and Director at the Directorate of Technology Development Fund-Defence Research and Development Organisation.
TransMedics Group Inc., which manufactures medical devices used in organ transplantation therapy for end-stage liver failure patients, has announced its acquisition of assets and intellectual property associated with Bridge to Life’s Ex-Vivo Organ Support System (“EVOSS”) and LifeCradle Heart Preservation Transport System (“LifeCradle”). EVOSS specifically facilitates the transport of lungs and hearts during transplantation through warm perfusion, while LifeCradle focuses on cold perfusion for heart transplants. Through this deal, TransMedics aims to strengthen its product portfolio in relation to organ transplantation.
In October 2023, Out \ Look on Out of Home McVitie’s Launches True Originals Brand Platform comes from PML Group Marketing Executive Aaron Poole. The release of McVitie’s master brand campaign called ‘True Originals’ signals a gauntlet thrown down amongst biscuit brands. The intention, according to the marketing communication endeavor, is to assert that when people think about biscuits, they should consider McVitie’s as their first choice because it is marked by originality, hence the name “True Original.” Over more than 180 years, it has grown into one of the UKIE’s dominant businesses with a long history as the market leader. However, copycats have forced a shake-up in the snack aisle, and so the brand must build mental availability if it is to remain top of mind for biscuit buyers.
Once upon a time, in February 2023, there was physical retail. Then Bezos said, “Let there be Prime,” and there was two-day delivery. And we saw that it was good. Since then, customers have increasingly expected orders to be delivered quickly, correctly, and with full visibility throughout the process since this landmark moment nearly 20 years ago. However, the major hurdle has always been what’s called the last mile—the distance between where an order ends up at its final distribution hub and when it actually gets into a customer’s hands. It is not only the most expensive and problematic part of a product’s journey but also an area of logistics management that is seeing some of its most exciting developments taking place.
One of the key factors driving the expansion of the market under study is the rising organ donation rate. The Association of Organ Procurement Organizations (AOPO) reported that more than 12,500 persons donated one or more organs in 2020, an increase of 6% from the year before. Deceased donors donated over 36,500 organs in 2020, an increase of nearly 2% from the previous year. Additionally, it stated that over the preceding seven years, more than 33,000 lives had been saved using organs from the deceased, surpassing those from the year before. Additionally, there were notable gains in DCD contributions, reaching more than 3,000 donors in 2020. Increased transplant diagnostic testing is required due to increased organ donation, which propels the market's expansion. Creating technologically sophisticated tissue products is one of the distinctive characteristics anticipated to fuel market expansion. Organ development using human induced pluripotent stem cells is a current scientific endeavor. In addition, cutting-edge technologies are used to overcome immunologic obstacles, including three-dimensional (3D) bioprinting, decellularization and recellularization, and interspecies organogenesis. Leading manufacturers are concentrating on introducing cutting-edge tissue products to the market. For instance, AlloSource introduced the AlloMend Ultra-Thick Acellular Dermal Matrix (ADM) in August 2021 to provide cutting-edge cellular and tissue products to aid surgeons in healing their patients. Thus, incorporating such distinctive tools will significantly accelerate market expansion. Therefore, such medical circumstances related has enhanced the market CAGR of Organ Transplantation in recent years.
However, The most common causes of organ failure are severe trauma, leukemia, poisoning, drug addiction, blood loss, sepsis, and other acute disorders. ly, there is a very high need for tissue and organ transplantation, particularly for the kidney, liver, heart, and lungs. Organ failure is primarily brought on by unhealthy eating patterns, alcohol intake, inactivity, and drug usage is another factor driving the growth of the Organ Transplantation market revenue.
Figure 1: Number of transplantation
The Organ Transplantation market segmentation, based on Product, includes tissue products, immunosuppressive drugs, preservation solutions, and others. The tissue products segment held the majority share in 2022, contributing around ~45% concerning the market revenue of Organ Transplantation. This is because the need for organ and tissue transplants is growing. A large population is now at risk of irreversible tissue damage due to the increased prevalence of diseases like diabetes, cancer, cardiovascular disease, renal disease, and Alzheimer's disease. This has increased the need for tissue transplantation, boosting the segment's revenue market growth for Organ Transplantation
The Organ Transplantation market data has been bifurcated by Application into Organ Transplantation and Tissue Transplantation. The Tissue Transplantation segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is because the most frequent surgical procedures around the world involve replacing the skin, cornea, bones, heart valves, tendons, nerves, and veins. The demand for tissue products is anticipated to increase due to the rise in burn and accident cases. Spain reported 102,362 injury accidents, according to the European Road Safety Observatory study. They are resulting in a demand for tissue transplants.
Figure 2: Organ Transplantation Market, by Application, 2023 & 2032 (USD Million)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Organ transplant Additionally, compared to Tissue Transplantation, minimally invasive Application is faster, safer, and needs less recovery time. Rising potential benefits such as less blood loss from Application, lower chance of muscle injury and infection, less postoperative discomfort, and faster recovery from degenerative disc disease, lumbar spinal stenosis, and ruptured disc Application are likely to drive sector growth throughout the projection period.
Based on End Users, the market segmentation for Organ Transplantation has been segmented into Hospitals, Transplant Centers, and others. Hospitals held the most significant segment share in 2022, increasing the number of surgeries and medical procedures carried out in hospitals. Most hospitals have easier access to well-defined organ databases that can confirm the availability of requested organs, enabling quicker medical intervention fueling the segment's revenue rise.
The fastest-growing segment in the Organ Transplantation industry is transplant centers. Due to the increasing demand for advanced healthcare facilities and transplant centers are an excellent choice for older persons as they offer individualized care and reduce the need for frequent hospital visits. The danger of infections acquired in hospitals is also reduced by treatment in transplant centers.
News:
The first participant in the Phase 2 BESTOW trial, which is testing the effectiveness of tegoprubart in preventing organ rejection in kidney transplant recipients, has been dosed, according to Eledon Pharmaceuticals, Inc. About 120 people undergoing kidney transplantation in the US and other countries will be enrolled in BESTOW, a multicenter, two-arm, active comparator medical study, to compare the safety, pharmacokinetics, and effectiveness of the anti-CD40 ligand antibody tegoprubart to the calcineurin inhibitor tacrolimus. The study's main goal is to compare people treated with tegoprubart to those treated with tacrolimus regarding graft function at twelve months post-transplant, as determined by the estimated glomerular filtration rate (eGFR). Improvements in permanent patient and graft survival have been linked to better graft function as measured by eGFR.
By Region, the study provides market insights for Organ Transplantation into North America, Europe, Asia-Pacific, and the Rest of the World. In North America, the market of Organ Transplantation accounted for USD 3.06 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Because of the ongoing development of novel transplantation goods for treatment, a well-developed healthcare system, and rising consumer spending on personal health. The strong presence of numerous large-scale biotechnology and medical device firms is also anticipated to fuel the market's revenue growth in North America.
Further, the significant countries studied in the market report for Organ Transplantation are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ORGAN TRANSPLANTATION MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Organ Transplantation market accounts for the second-largest market share The rise in these operations and the critical measures taken by various governments to enhance awareness of organ donation in the area can be credited with the expansion. Further, the Germany market of Organ Transplantation held the largest market share, and the UK market of Organ Transplantation was the fastest-growing market in the European region.
The Asia-Pacific Organ Transplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. Growing number of chronic diseases and the increasing frequency of traffic accidents permanently destroy organs and necessitate replacing them with healthy organs to preserve the patient's life. The expansion of the Asia Pacific transplantation market's revenue is also driven by leading companies' ongoing improvements in transplantation technology in these nations. Moreover, the China market of Organ Transplantation held the largest market share, and the India market of Organ Transplantation was the fastest-growing market in the Asia-Pacific region.
Major industry players are investing a lot of money in R&D to broaden their product offerings, which will fuel further market expansion of the Organ Transplantation. Along with essential industry activities, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic initiatives to enhance their footprint. Organ transplant industry competitors must provide affordable products to grow and thrive in a market that is becoming increasingly competitive.
Manufacturing locally to cut operational costs is one of the leading business methods manufacturers use in the worldwide organ transplantation industry to benefit customers and increase the market sector. In recent years, Organ Transplantation industry has provided medicine with some of the most significant benefits. The market of Organ Transplantation major player such as Natera Inc, NephroSant, and others are working to expand the market demand by investing in research and development activities.
With an emphasis on women's health, cancer, and organ health, Natera, Inc. is a clinical genetic testing business with headquarters in Austin, Texas. Natera specializes in non-invasive, cell-free DNA testing technologies. In September 2022, Prospera with Quantification, a cfDNA test for kidney rejection, was introduced by Natera Inc., one of the leading companies redefining healthcare via genetic and cell-free DNA (cfDNA) testing.
Also, A biotechnology business called NephroSant creates ground-breaking diagnostic instruments for the lifetime monitoring of kidney health and the early diagnosis of risk of kidney illness or injury. In March 2022, The Evaluation of QSant for Underlying Allograft Rejection (AQUA) trial began with the recruitment of the first patient by a biotechnology company committed to accelerating the assessment of early kidney injury.
Key Companies in the Organ Transplantation market includes
Organ Transplantation Industry Developments
March 2022:Immucor, Inc., a business specializing in transfusion and transplantation diagnostics, recently announced the addition of two new products to its portfolio of transplant diagnostics, proving its continued dedication to recent developments in the histocompatibility sector.
March 2022:To focus on the commercialization of HepatoPredict, a predictive gene expression signature test to determine which patients may benefit from liver transplantation, Biocartis, and Ophiomics collaborated.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 7.3 billion |
| Market Size 2024 | USD 7.99 billion |
| Market Size 2032 | USD 15.16 billion |
| Compound Annual Growth Rate (CAGR) | 8.33% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product , Application, End Use and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novartis International AG (Switzerland), Terumo Medical Corporation (US), Transonic (US), Hoffmann-La Roche Ltd. (Switzerland), ASTELLAS PHARMA Inc. (Japan), Preservation Solutions Inc. (US),Organ OX Limited (UK),Bio-Med PVT. Ltd. (US),Transplant Biomedical (UK),Trans Medic Inc. (US) |
| Key Market Opportunities | Rapidly developing economies |
| Key Market Dynamics | Growing prevalence of chronic diseases Increasing prevalence of renal diseases |
Frequently Asked Questions (FAQ) :
The Organ Transplantation market size was valued at USD 7.3 Billion in 2023.
The market for Organ Transplantation is projected to grow at a CAGR of 8.33% during the forecast period, 2024-2032.
North America had the largest share in the market for Organ Transplantation.
The key players in the market for Organ Transplantation are Novartis International AG (Switzerland), Terumo Medical Corporation (US), Transonic (US), Hoffmann-La Roche Ltd. (Switzerland), A.
The Tissue Products category dominated the market for Organ Transplantation in 2022.
The Tissue Transplantation had the largest share in the Organ Transplantation market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
